| Not Yet Recruiting | JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer Cervical Cancer | Phase 2 | 2026-04-01 |
| Recruiting | A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Ca Triple Negative Breast Cancer | Phase 3 | 2026-03-17 |
| Not Yet Recruiting | A Study of JSKN027 in Patients With Advanced Solid Tumors Advanced Malignant Solid Tumor | Phase 1 | 2026-03-15 |
| Not Yet Recruiting | JSKN016HC in Patients With Advanced or Metastatic Solid Malignant Tumors Advanced Solid Tumor Malignancies | Phase 1 | 2026-03-01 |
| Not Yet Recruiting | JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC) | Phase 1 / Phase 2 | 2026-01-01 |
| Not Yet Recruiting | A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Pa Non Small Cell Lung Cancer (NSCLC) | Phase 2 | 2025-12-10 |
| Recruiting | JSKN022 in Subjects With Advanced Malignant Solid Tumors Advanced Malignant Solid Tumors | Phase 1 | 2025-10-23 |
| Recruiting | Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer | Phase 1 / Phase 2 | 2025-06-01 |
| Recruiting | Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC Advanced Non-small Cell Lung Cancer | Phase 1 | 2025-04-02 |
| Not Yet Recruiting | Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study Advanced Non-small Cell Lung Cancer | Phase 2 | 2025-01-17 |
| Not Yet Recruiting | JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancers | Phase 3 | 2025-01-15 |
| Not Yet Recruiting | JSKN033 in Chinese Subjects with Advanced Malignant Tumors Advanced Malignant Tumors | Phase 1 / Phase 2 | 2025-01-15 |
| Recruiting | To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors Advanced Malignant Solid Tumor | Phase 1 | 2024-04-30 |
| Terminated | JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors Advanced Solid Tumor | Phase 1 / Phase 2 | 2024-01-18 |
| Recruiting | JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subj Breast Cancer | Phase 3 | 2023-12-01 |
| Active Not Recruiting | Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors Advanced Solid Tumor | Phase 1 / Phase 2 | 2023-03-15 |
| Recruiting | Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer Advanced Non-small Cell Lung Cancer | Phase 2 | 2022-07-15 |
| Terminated | Clinical Study of KN052 in Chinese Subjects With Advanced Solid Tumors Advanced Solid Tumor | Phase 1 | 2022-05-27 |
| Terminated | Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer HER2-positive Metastatic Breast Cancer | — | 2022-05-25 |
| Unknown | KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma. Advanced Pancreatic Ductal Adenocarcinoma | Phase 3 | 2022-01-20 |
| Terminated | KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent Advanced Non-small Cell Lung Cancer | Phase 2 / Phase 3 | 2021-10-28 |
| Unknown | Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Breast Cancer | Phase 2 | 2021-08-09 |
| Terminated | KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma Advanced HCC | Phase 1 / Phase 2 | 2021-06-07 |
| Completed | Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors HER2-positive Solid Tumors | Phase 2 | 2020-12-07 |
| Terminated | KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Ca Thymic Carcinoma | Phase 2 | 2020-12-02 |
| Unknown | KN046 in Subjects With Advanced Squamous Non-small Cell Lung Cancer Squamous Non-small-cell Lung Cancer | Phase 3 | 2020-09-14 |
| Unknown | Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer Metastatic Breast Cancer | Phase 2 | 2019-12-31 |
| Completed | Efficacy and Safety Study of KN019 in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexat Rheumatoid Arthritis | Phase 2 | 2019-11-08 |
| Unknown | Study of KN046 With Chemotherapy in First Line Advanced NSCLC Non-small Cell Lung Cancer | Phase 2 | 2019-09-04 |
| Completed | KN046 in Subjects With Late Stage Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma | Phase 2 | 2019-06-21 |
| Unknown | KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer Breast Cancer, Gastric/Gastroesophageal Junction Cancer | Phase 1 | 2019-06-18 |
| Completed | KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer Gastric/Gastroesophageal Junction Cancer | Phase 2 | 2019-06-17 |
| Completed | A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer Triple-negative Breast Cancer | Phase 1 / Phase 2 | 2019-05-30 |
| Terminated | KN046 in Patients With Advanced Non-small Cell Lung Cancer Stage IV Non-small Cell Lung Cancer | Phase 2 | 2019-05-05 |
| Completed | KN046 in Subjects With Advanced Solid Tumors and Lymphoma Advanced Solid Tumors, Lymphoma | Phase 1 | 2018-12-18 |
| Completed | Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer Breast Cancer, Gastric Cancer | Phase 1 | 2018-09-17 |